Uncategorized

Novartis cuts two programs in cancer-related blood clots

Published

5 hours ago

on

April 20, 2026

By

Temp User

Novartis has axed two late-stage programs in cancer-related blood clots after observing “inferior efficacy” in a clinical trial.

The move marks a setback for a candidate that Novartis out-licensed in 2019, then

Related Topics:

Leave a Reply

Uncategorized9 years ago

These ’90s fashion trends are making a comeback in 2017
Contributors9 years ago

The final 6 ‘Game of Thrones’ episodes might feel like a full season
Uncategorized9 years ago

According to Dior Couture, this taboo fashion accessory is back
Uncategorized9 years ago

Phillies’ Aaron Altherr makes mind-boggling barehanded play
Uncategorized9 years ago

Uber and Lyft are finally available in all of New York State
Uncategorized9 years ago

The old and New Edition cast comes together to perform

Exit mobile version